Skip to main content

Advertisement

SpringerLink
Log in

Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO)

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Minodronate is a potent nitrogen-containing bisphosphonate that can be administered according to a monthly (every 4 weeks) dosing regimen. A 6-month, cluster-randomized, open-label, multicenter, crossover trial was conducted to test the preference of Japanese patients with osteoporosis for monthly bisphosphonate versus weekly bisphosphonate. One hundred and forty-seven patients (postmenopausal women and men) with primary osteoporosis were recruited at eight outpatient clinics. The clinics were randomized into two groups according to the dosing protocol—monthly minodronate followed by weekly alendronate or risedronate for a total of 24 weeks, or weekly alendronate or risedronate followed by monthly minodronate for 24 weeks. Patient preference for either the monthly or weekly bisphosphonate regimen was evaluated using a preference questionnaire. One hundred and fifteen patients (78.2 %) who completed the trial were processed for the analyses. Significantly more patients preferred the monthly bisphosphonate regimen (65.2 %) than the weekly bisphosphonate regimen (15.7 %) (P = 0.007). ‘Dosing schedule fits lifestyle better’ was the most common reason given for the patient preference for both the monthly (32.0 %) and weekly bisphosphonate (33.3 %) regimens. Significantly more patients found the monthly bisphosphonate regimen to be more convenient (73.0 %) than the weekly bisphosphonate regimen (13.9 %) (P < 0.0001). The safety profiles of the two regimens were similar. The present trial demonstrated a strong patient preference for and the convenience of the monthly bisphosphonate regimen over the weekly bisphosphonate regimen in Japanese patients with osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Confavreux CB, Canoui-Poitrine F, Schott AM, Ambrosi V, Tainturier V, Chapurlat RD (2012) Persistence at 1 year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance database. Eur J Endocrinol 166:735–741

    Article  CAS  PubMed  Google Scholar 

  2. Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429–1437

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Okazaki R, Hagino H, Ito M, Sone T, Nakamura T, Mizunuma H, Fukunaga M, Shiraki M, Nishizawa Y, Ohashi Y, Matsumoto T (2012) Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis. Osteoporos Int 23:1737–1745

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V, Masanauskaite D (2005) Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21:1895–1903

    Article  CAS  PubMed  Google Scholar 

  5. Hadji P, Minne H, Pfeifer M, Bourgeois P, Fardellone P, Licata A, Devas V, Masanauskaite D, Barrett-Connor E (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 75:303–310

    Article  CAS  PubMed  Google Scholar 

  6. Payer J, Killinger Z, Sulková I, Celec P (2008) Preferences of patients receiving bisphosphonates—how to influence the therapeutic adherence. Biomed Pharmacother 62:122–124

    Article  CAS  PubMed  Google Scholar 

  7. Payer J, Cierny D, Killinger Z, Sulková I, Behuliak M, Celec P (2009) Preferences of patients with post-menopausal osteoporosis treated with bisphosphonates—the VIVA II study. J Int Med Res 37:1225–1259

    Article  CAS  PubMed  Google Scholar 

  8. Kastelan D, Lozo P, Stamenkovic D, Miskic B, Vlak T, Kolak Z, Milas Ahic J, Altabas V, Crncevic Orlic Z, Korsic M (2009) Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study. Clin Rheumatol 28:321–326

    Article  PubMed  Google Scholar 

  9. Makita K, Okano H, Furuya T, Urano T, Hirabayashi H, Kumakubo T, Iwamoto J (2014) Survey of the utility of once-monthly bisphosphonate treatment for improvement of medication adherence in osteoporosis patients in Japan. J Bone Miner Metab 33:55–60

    Article  PubMed  Google Scholar 

  10. Orimo H, Sugioka Y, Fukunaga M, Muto Y, Hotokebuchi T, Gorai I, Nakamura T, Kushida K, Tanaka H, Ikai T, Ohhashi Y (1998) Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 16:139–150

    Article  Google Scholar 

  11. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H, Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337

    Article  CAS  PubMed  Google Scholar 

  12. Fujiwara S, Sone T, Yamazaki K, Yoshimura N, Nakatsuka K, Masunari N, Fujita S, Kushida K, Fukunaga M (2005) Heel bone ultrasound predicts non-spine fracture in Japanese men and women. Osteoporos Int 16:2107–2112

    Article  CAS  PubMed  Google Scholar 

  13. Wüster C, Heilmann P, Pereira-Lima J, Schlegel J, Anstätt K, Soballa T (1998) Quantitative ultrasonometry (QUS) for the evaluation of osteoporosis risk: reference data for various measurement sites, limitations and application possibilities. Exp Clin Endocrinol Diabetes 106:277–288

    Article  PubMed  Google Scholar 

  14. Uchida S, Taniguchi T, Shimizu T, Kakikawa T, Okuyama K, Okaniwa M, Arizono H, Nagata K, Santora AC, Shiraki M, Fukunaga M, Tomomitsu T, Ohashi Y, Nakamura T (2005) Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab 23:382–388

    Article  CAS  PubMed  Google Scholar 

  15. Kishimoto H, Fukunaga M, Kushida K, Shiraki M, Itabashi A, Nawata H, Nakamura T, Ohta H, Takaoka K, Ohashi Y, Risedronate Phase III Research Group (2006) Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5 mg once-daily dosage regimen. J Bone Miner Metab 24:405–413

    Article  CAS  PubMed  Google Scholar 

  16. Sampalis JS, Adachi JD, Rampakakis E, Vaillancourt J, Karellis A, Kindundu C (2012) Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence. J Bone Miner Res 27:202–210

    Article  CAS  PubMed  Google Scholar 

  17. Cotté FE, Fardellone P, Mercier F, Gaudin AF, Roux C (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145–155

    Article  PubMed  PubMed Central  Google Scholar 

  18. Rizzoli R, Reginster JY, Boonen S, Bréart G, Diez-Perez A, Felsenberg D, Kaufman JM, Kanis JA, Cooper C (2011) Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int 89:91–104

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Iwamoto J (2014) Monthly risedronate for the treatment of postmenopausal osteoporosis. Pharm Anal Acta 5:285

    Article  Google Scholar 

Download references

Acknowledgments

This study was supported by The Waksman Foundation of Japan INC.

Conflict of interest

We have no conflict of interest and disclosure.

Author information

Authors and Affiliations

  1. Institute for Integrated Sports Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan

    Jun Iwamoto

  2. Department of Orthopaedic Surgery, Keiyu Orthopaedic Hospital, Gunma, 374-0011, Japan

    Jun Iwamoto

  3. Iidabashi Ladies’s Clinic, Tokyo, 102-0072, Japan

    Hiroya Okano

  4. Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, 162-0054, Japan

    Takefumi Furuya

  5. Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-0033, Japan

    Tomohiko Urano

  6. Department of Orthopaedic Surgery, Kyorin University School of Medicine, Tokyo, 181-8611, Japan

    Masaichi Hasegawa

  7. Department of Orthopedics, Tokyo Adventist Hospital, Tokyo, 167-8507, Japan

    Hisashi Hirabayashi

  8. Kumakubo Orthopedics Clinic, Tokyo, 165-0025, Japan

    Takami Kumakubo

  9. Makita Obstetrics and Gynecology Clinic, Saitama, 352-0021, Japan

    Kazuya Makita

Authors
  1. Jun Iwamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroya Okano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takefumi Furuya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tomohiko Urano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masaichi Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hisashi Hirabayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takami Kumakubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kazuya Makita
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun Iwamoto.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iwamoto, J., Okano, H., Furuya, T. et al. Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO). J Bone Miner Metab 34, 201–208 (2016). https://doi.org/10.1007/s00774-015-0653-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-015-0653-7

Keywords

Search

Navigation